Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Z1900000

Zidovudine

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

3′-Azido-3′-deoxythymidine, AZT, Azidothymidine, ZDV, Zidovudine

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C10H13N5O4
Numero CAS:
Peso molecolare:
267.24
Beilstein:
3595791
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

zidovudine

Produttore/marchio commerciale

EDQM

Punto di fusione

113-115 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
HBOMLICNUCNMMY-XLPZGREQSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Zidovudine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Reverse transcriptase inhibitor active against HIV-1 virus.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Health hazard

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Carc. 2 - Muta. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 1

1 of 1

Tenofovir ≥98% (HPLC)

Sigma-Aldrich

SML1795

Tenofovir

Muki Shey et al.
The Cochrane database of systematic reviews, (3)(3), CD005481-CD005481 (2009-07-10)
The human immunodeficiency virus (HIV) has become one of the greatest challenges to global public health. In 2007 UNAIDS estimated that 33.2 million people were living with HIV. Currently recommended regimens for initiating HIV treatment consist of either a non-nucleoside
D M Simpson
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 29(1), 19-34 (1999-08-05)
Human immunodeficiency virus (HIV)-associated dementia (HIVD) has been reported in up to 15% of HIV-infected adult patients. Although the pathogenesis of HIVD remains unclear, HIV probably plays an important role in the syndrome, as evidenced by the correlation between cerebrospinal
Tomas Cihlar et al.
Antiviral research, 85(1), 39-58 (2009-11-06)
Twenty-five years ago, nucleoside analog 3'-azidothymidine (AZT) was shown to efficiently block the replication of HIV in cell culture. Subsequent studies demonstrated that AZT acts via the selective inhibition of HIV reverse transcriptase (RT) by its triphosphate metabolite. These discoveries
Cátia Teixeira et al.
European journal of medicinal chemistry, 46(4), 979-992 (2011-02-25)
The first anti-HIV drug, zidovudine (AZT), was approved by the FDA a quarter of a century ago, in 1985. Currently, anti-HIV drug-combination therapies only target HIV-1 protease and reverse transcriptase. Unfortunately, most of these molecules present numerous shortcomings such as
R Bendayan et al.
Pharmacotherapy, 15(3), 338-344 (1995-05-01)
In humans and various animal species, 3'-azido-3'-deoxythymidine (AZT) is in part eliminated by the kidneys, where it undergoes significant tubular secretion. The goal of this project was to develop, in a continuous renal epithelial cell line (LLCPK1), a model of

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.